aldafermin

Recombinant proteinexperimental

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ngm282

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06654726Phase 2/Phase 3 (Phase 3)Oct 21, 2024NGM Biopharmaceuticals, Inc
NCT05130047Phase 2Nov 30, 2021Mayo Clinic, NGM Biopharmaceuticals, Inc
NCT04828265Phase 1Apr 1, 2021NGM Biopharmaceuticals, Inc
NCT04823702Phase 1Apr 1, 2021NGM Biopharmaceuticals, Inc
NCT04210245Phase 2Dec 31, 2019NGM Biopharmaceuticals, Inc
NCT04179630Phase 1Nov 8, 2019NGM Biopharmaceuticals, Inc
NCT03912532Phase 2Apr 1, 2019NGM Biopharmaceuticals, Inc
NCT02704364Phase 2Feb 1, 2016NGM Biopharmaceuticals, Inc
NCT02649062Phase 1/Phase 2 (Phase 2)Dec 1, 2015NGM Biopharmaceuticals, Inc
NCT02443116Phase 2May 1, 2015NGM Biopharmaceuticals, Inc
NCT02135536Phase 2May 1, 2014NGM Biopharmaceuticals, Inc
NCT02026401Phase 2Feb 1, 2014NGM Biopharmaceuticals, Inc
NCT01943045Phase 2Sep 1, 2013NGM Biopharmaceuticals, Inc
NCT01776528Phase 1Jan 1, 2013NGM Biopharmaceuticals, Inc
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NGM Biopharmaceuticals, IncFor profit141332013
Mayo ClinicAcademic/Hospital1112021
2 organizations
Page 1 / 1